RETHINKDEPRESSION
LIVE

Serial Number

87463877

Owner

H. Lundbeck A/S

Attorney

Maren C. Perry

Filing Date

May 25, 2017

Add to watchlist:

No watchlists yet
View on USPTO

RETHINKDEPRESSION Trademark

Serial Number: 87463877 • Registration: 5604219

RETHINKDEPRESSION is a trademark filed by H. Lundbeck A/S on May 25, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

May 25, 2017

Registration Date

November 13, 2018

Published for Opposition

August 28, 2018

Goods & Services

[ Education services, namely, arranging and conducting seminars, conferences, symposiums, workshops and courses in the field of medical research and development, science, clinical studies, tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; educational and training services in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders; providing the aforementioned services electronically, on-line, via cable or Internet or other electronic media; arranging and conducting expert forums, including on-line in the form of seminars, conferences, symposiums, workshops and courses in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders; providing on-line training programs in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders; providing on-line publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders ]

[ Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, falls, movement disorders and diseases, schizophrenia, bipolar disorder and disease, ADHD, oncology, pain, alcoholism and dependency; medical preparations, substances, reagents and diagnostic agents for medical purposes ]

[ Medical and therapeutic services relating to the treatment and prevention of brain and central nervous system diseases and disorders; healthcare services, namely, clinical healthcare; medical, clinical, therapeutic clinical services in the field of brain and central nervous system diseases and disorders; healthcare information services; medical services in the field of psychiatry and psychology and medical treatment of central nervous system related diseases and disorders; medical advice related to the treatment of central nervous system diseases and disorders; healthcare and medical services related to the treatment and prevention of central nervous system and brain diseases and disorders; ] providing medical and medicinal information in the field of diagnostics, medicine and pharmaceuticals for the treatment and prevention of diseases and disorders of the central nervous system; providing on-line medical information, namely, data and analyses designed to provide patients and clients with customized information regarding diagnosis and treatment

[ Scientific and technological services, namely, research and design in the field of pharmaceuticals for the treatment and prevention of diseases and disorders of the central nervous system; medical and scientific research, namely, conducting clinical trials for others; clinical studies tests and trials; industrial analysis and research in the field of research and development relating to the treatment and prevention of diseases and disorders of the central nervous system; pharmaceutical research and development services; medical research; providing information in the field of research and development related to the treatment and prevention of central nervous system diseases and disorders ]

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
May 6, 2025 NURC
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Apr 15, 2025 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Apr 15, 2025 8.PR
AMENDMENT UNDER SECTION 7 - PROCESSED
Apr 15, 2025 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 7, 2025 APRE
TEAS SECTION 8 RECEIVED
Nov 8, 2024 ES8R
TEAS SECTION 7 REQUEST RECEIVED
Nov 8, 2024 ES7R
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 22, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 22, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Mar 22, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 22, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 22, 2024 REAP
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 13, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Nov 13, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 28, 2018 NPUB
PUBLISHED FOR OPPOSITION
Aug 28, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 8, 2018 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Jul 23, 2018 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jul 20, 2018 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 16, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 16, 2018 XAEC
ASSIGNED TO LIE
Jul 16, 2018 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 16, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 16, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 16, 2018 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 24, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 24, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 24, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 3, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 2, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 2, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 10, 2017 GNRN
NON-FINAL ACTION E-MAILED
Jul 10, 2017 GNRT
NON-FINAL ACTION WRITTEN
Jul 10, 2017 CNRT
ASSIGNED TO EXAMINER
Jul 3, 2017 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 2, 2017 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 1, 2017 NWOS
NEW APPLICATION ENTERED
May 29, 2017 NWAP